Exhibit 99.1
(A.R.T. LOGO)
     
 
  4 Mill Ridge Lane
 
  Mill Ridge Farm
 
  Chester, NJ 07930
 
  Main: 908-879-1400
 
  Fax: 908-879-9191
 
  www.adamsrt.com
ADAMS RESPIRATORY THERAPEUTICS REPORTS
FISCAL 2007 FIRST QUARTER FINANCIAL RESULTS
Excellent business execution drives solid financial and operational performance
First Quarter Financial Highlights:
    Net sales increased 92% to $90.1 million.
 
    Pretax income increased 26% to $25.4 million.
 
    Income per diluted share increased 22% to $0.44 inclusive of a one-time pretax charge of $9.7 million, or $0.17 per diluted share.
CHESTER, N.J. (Nov. 8, 2006) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fiscal first quarter ended Sep. 30, 2006.
Commenting on the Company’s fiscal 2007 first quarter results, Michael J. Valentino, president and CEO said, “With net sales of $90.1 million, we achieved solid year-over-year increases in pre-tax income and income per diluted share of 26 percent and 22 percent, respectively. These results are very impressive, especially given the fact that our pre-tax income of $25.4 was inclusive of a one-time pre-tax charge of $9.7 million – or $0.17 in diluted earnings per share – related to the July 31, 2006, repurchase of the Fort Worth manufacturing assets.”
Valentino added, “I am very proud of the strong financial and operational achievements made during the quarter. These results are truly reflective of the excellent level of business execution we have come to be known for in the industry. We are operating from a position of strength across all aspects of our business. In fact, according to Information Resources Inc., or IRI, data through September 2006, consumption for our adult Mucinex® franchise is up 50 percent, and consumption for Delsym® higher by 25 percent compared to year-ago levels. In addition, as we enter this upcoming cough/cold season we have vastly improved manufacturing capabilities and we have significantly better product distribution and retail positioning for our key brands.”
First Quarter Financial Results
Net sales for the quarter rose 92 percent to $90.1 million from $47.0 million in the fiscal 2006 first quarter, benefiting from improved depth and quality of distribution of Mucinex® DM, the launch of Children’s Mucinex®, and sales of the newly acquired Delsym® product line.

 


The following information was filed by Adams Respiratory Therapeutics, Inc. on Wednesday, November 8, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account